Are Synthetic Data Derivatives the Future of Translational Medicine?

As noted in this Editor’s Page previously, the rising cost of developing new cardiovascular therapies cannot be sustained in the long-term [(1)][1]. Accordingly, there is a critical need for new methodologies that can improve the speed, efficiency, and success rate of efforts to develop new

[1]  Nikolaos A. Patsopoulos,et al.  A pragmatic view on pragmatic trials , 2011, Dialogues in clinical neuroscience.

[2]  Michael A. Proschan,et al.  Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 1996 .

[3]  D. Stryer,et al.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.

[4]  B. Fitzgerald.  Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule , 2015 .

[5]  N. Schork,et al.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? , 2011, Personalized medicine.

[6]  Robert S Lane.  An interview with Robert S. Lane, Ph.D. Interviewed by Vicki Glaser. , 2010, Vector borne and zoonotic diseases.

[7]  B R Davis,et al.  Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. , 1996, American journal of hypertension.

[8]  Michael Berk,et al.  The limitations of using randomised controlled trials as a basis for developing treatment guidelines , 2017, Evidence Based Journals.

[9]  Peter Szolovits,et al.  Evaluating the state-of-the-art in automatic de-identification. , 2007, Journal of the American Medical Informatics Association : JAMIA.

[10]  D. DeMets,et al.  Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. , 2001, Controlled clinical trials.

[11]  Philip R. O. Payne,et al.  Biomedical Informatics and Outcomes Research: Enabling Knowledge-Driven Health Care , 2009, Circulation.

[12]  Harlan M Krumholz,et al.  Open science and data sharing in clinical research: basing informed decisions on the totality of the evidence. , 2012, Circulation. Cardiovascular quality and outcomes.

[13]  Douglas L. Mann,et al.  The Rising Cost of Developing Cardiovascular Therapies and Reproducibility in Translational Research , 2017, JACC. Basic to translational science.

[14]  N. Shah,et al.  A 'green button' for using aggregate patient data at the point of care. , 2014, Health affairs.